Civi Biopharma is a US-based, privately held biopharmaceutical company focused on creating novel therapies against cardiovascular and metabolic diseases
Civi Biopharma is a US-based, privately held biopharmaceutical company focused on creating novel therapies against cardiovascular and metabolic diseases. The company has developed a novel RNA-targeted drug against PCSK-9, utilizing Roche's proprietary LNA technology.